Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 3Terminated 2Withdrawn 1Recruiting 1Not yet recruiting 1Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Lung Neoplasms 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Drug Therapy 107Cisplatin 97Radiotherapy 89Carboplatin 87Bevacizumab 79Oxaliplatin 74tislelizumab 68Capecitabine 67Cyclophosphamide 65Gemcitabine 64toripalimab 61Paclitaxel 57Specimen Handling 55pembrolizumab 54sintilimab 53Surgical Procedures, Operative 52anlotinib 49Magnetic Resonance Spectroscopy 49Fluorouracil 49Immune Checkpoint Inhibitors 43Blood Specimen Collection 42130-nm albumin-bound paclitaxel 42Standard of Care 39camrelizumab 36fludarabine 35lenvatinib 34Leucovorin 34venetoclax 30Radiosurgery 30Immunotherapy 30

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Not yet recruiting × OTHER × Pharmacokinetics × Clear all
NCT07436858 2026-02-27

Whole Body HER2 Quantification With 89Zr-Trastuzumab PET/CT to Asses Zr-trastuzumab Accumulation in HER2-mutated and HER2-overexpressing Metastatic Non-small Cell Lung Cancer

The Netherlands Cancer Institute

Phase 1 Not yet recruiting
20 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡